GeneChem Inc.
3
29M
2
0.12
0.33
2
- Areas of investment
Summary
In 1997 was created GeneChem Inc., which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Daejeon. The fund was located in Asia if to be more exact in South Korea.
The fund was created by Jinsuk Woo.
The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2007. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2011. This GeneChem Inc. works on 38 percentage points more the average amount of lead investments comparing to the other organizations.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight BioVex, Cyclacel Pharmaceuticals. For fund there is no match between the location of its establishment and the land of its numerous investments - United Kingdom.
The usual cause for the fund is to invest in rounds with more than 10 partakers. Despite the GeneChem Inc., startups are often financed by Scottish Equity Partners, West Deutsche Landesbank Girozentrale, Technomark Medical Ventures. The meaningful sponsors for the fund in investment in the same round are Scottish Equity Partners, Temasek Holdings, Avalon Ventures. In the next rounds fund is usually obtained by Scottish Equity Partners, Triathlon Medical Venture Partners, New Science Ventures.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.12
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (3)
- Health Care (2)
- Medical (2)
- Pharmaceutical (1)
- Therapeutics (1)
- Investments by region
-
- United Kingdom (2)
- United States (1)
- Peak activity year
- 2003
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 24
- Avg. valuation at time of investment
- 500M
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
- Avg. multiplicator
- 8.61
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| BioVex | 06 Oct 2003 | Biotechnology, Health Care, Medical | Late Stage Venture | 23M | England, United Kingdom, United Kingdom |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.